Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 8Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Neoplasms 4Multiple Myeloma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Parasomnias 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Lymphoma 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Head and Neck Neoplasms 2HIV Infections 2Fatigue 2Erectile Dysfunction 2Carcinoma, Hepatocellular 2Vitamin D Deficiency 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Untreated Advanced Non-small Cell Lung Cancer 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1

Interventions

Morphine 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER_GOV × Breakthrough Pain × Clear all
NCT05037539 2022-08-31

Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain

Department of Medical Services Ministry of Public Health of Thailand

Phase 1/2 Completed
20 enrolled

Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡